The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture
Open accessPublished version of a preprint
Abstract
Optimal treatment of cancer requires diagnostic methods to facilitate therapy choice and prevent ineffective treatments. Direct assessment of therapy response in viable tumor specimens could fill this diagnostic gap. Therefore, we designed a microfluidic platform for assessment of patient treatment response using tumor tissue slices under precisely controlled growth conditions. The optimized Cancer-on-Chip (CoC) platform maintained viability and sustained proliferation of breast and prostate tumor slices for 7 days. No major changes in tissue morphology or gene expression patterns were observed within this time frame, suggesting that the CoC system provides a reliable and effective way to probe intrinsic chemotherapeutic sensitivity of tumors. The customized CoC platform accurately predicted cisplatin and apalutamide treatment response in breast and prostate tumor xenograft models, respectively. The culture period for breast cancer could be extended up to 14 days without major changes in tissue morphology and viability. These culture characteristics enable assessment of treatment outcomes and open possibilities for detailed mechanistic studies. SIGNIFICANCE: The Cancer-on-Chip platform with a 6-well plate design incorporating silicon-based microfluidics can enable optimal patient-specific treatment strategies through parallel culture of multiple tumor slices and diagnostic assays using primary tumor material.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Breast PDX tumor tissue slices cultured in ex vivo condition and in CoC platform for up to 14 days. A, We used five independent breast PDX tumors in five independent experiments to establish optimized culture condition for tumor slices in our CoC platform. From each breast PDX tumor, tissue slices were cultured in ex vivo 6-well plate and CoC device for up to 14 days and evaluated for tissue morphology [hematoxylin and eosin (H&E) staining], DAPI (blue nuclei), proliferation (EdU incorporation, red nuclei), Ki67 (brown nuclei), and apoptosis (TUNEL staining, green nuclei). Scale bar, 50 μm. B and C, Quantification of the fraction of EdU-positive and TUNEL-positive cells for 5 breast PDX tissue slices (derived from individual PDX tumors) cultured for up to day 7 (B) and day 14 (C). For each breast PDX tumor and each condition, tissue slices were imaged, and ten random fields of view were quantified from each breast PDX slice. Each data point in the graph represents one image field. Error bar represents the SEM for the five independent tumors performed in five independent experiments. D, Representative image showing breast PDX tumors (n = 3) labeled with geminin (red nuclei) and DAPI (blue nuclei). Scale bar, 50 μm. E, QIBC analysis of three independent breast PDX tumors with more than 3,000 cells analyzed for each are shown in each condition. F, Quantification of geminin-positive cells showed CoC at day 7 had similar cell proliferation profile as in day 0 than ex vivo condition. Error bar, SEM. NS, not significant; D0, day 0; D7, day 7, D14, day 14. NS, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.](https://figures.cochat.ai/paper-figures/417f03dd7fe24da08b8fe93a59973cda/a-microfluidic-cancer-on-chip-platform-predicts-drug-response-using-organotypic-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, the prostate cancer tumor slices maintained their viability, morphology, proliferation potential and gene expression profiles in the microfluidic device for 7 days, allowing for the assessment of the chemotherapeutic sensitivity of the tumors.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Chakrabarty et al., 2022
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The administration of apalutamide resulted in decreased AR expression, an increase in apoptotic cells and a significant decrease in proliferation, which replicates the effect of antiandrogen treatment in ex vivo cultures and in vivo.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Chakrabarty et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“251 Samtools and PICARD programs were used on the aligned files to obtain the mapping statistics and other 252 RNAseq metrics(29).”
MethodRobinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364 · cited 1×
“8 Bioconductor package edgeR was used for differential expression analysis (33).”
MethodfeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · cited 1×
“We used 255 the feature Counts program to generate the count table for differential expression analysis (32).”
MethodGraph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Kim, D., Paggi, J. M., Park, C., Bennett, C., & Salzberg, S. L. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0201-4 · Cited by 15,022 · cited 1×
“The 249 trimmed and processed fastqc files were separately aligned to human and mouse genomes (GRCh38 and 250 GRCm38 versions) downloaded from GENCODE respectively using HISAT2 (a splice aware aligner)(28).”
MethodStringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298 · cited 1×
“Expression analysis was performed for both human and mouse mapped reads using 254 StringTie using the reference only approach and the gene abundance tables were obtained (31).”
MethodPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“Defining features of this 405 microfluidic system are: (1) relatively large (tumor) tissue slices can be loaded, (2) flow of culture media 406 both above and under the tissue slice to sustain constant delivery of nutrients and gasses and removal of 407 waste products, (3) mainly silicon-based components, (4) standard…”
BackgroundRottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956 · cited 1×
“For example, (breast) cancer patients with pathogenic 77 BRCA1/2 mutations are homologous recombination (HR) deficient, which makes them eligible for PARP 78 inhibitor (PARPi) therapy (6).”
BackgroundSelf-citationHuman 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation
Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., Charest, J. L., Moretti, M., & Kamm, R. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417115112 · Cited by 723 · cited 1×
“engineering for controlled culture of cells or tissue specimens (13,14).”
BackgroundFLEXBAR—Flexible Barcode and Adapter Processing for Next-Generation Sequencing Platforms
Dodt, M., Roehr, J., Ahmed, R., & Dieterich, C. (2012) · Biology · doi:10.3390/biology1030895 · Cited by 719 · cited 1×
“Adapter trimming and removal 248 of homo-polymers were performed using FLEXBAR and reads less than 25 bases were discarded (27).”
MethodLukas, C., Savic, V., Bekker-Jensen, S., Doil, C., Neumann, B., Sølvhøj Pedersen, R., Grøfte, M., Chan, K. L., Hickson, I. D., Bartek, J., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2201 · Cited by 667 · cited 1×
“A similar phenomenon has been observed before in cells and was shown to be due to 446 replication stress (50), suggesting that the culture conditions presented here led to similar replication 447 problems.”
Background
Cited by
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Organ-on-a-chip meets artificial intelligence in drug evaluation
Deng, S., Li, C., Cao, J., Cui, Z., Du, J., Fu, Z., Yang, H., & Chen, P. (2023) · Theranostics · doi:10.7150/thno.87266 · Cited by 260
“At present, tumor OoCs also include colorectal [55, 140], ovarian [141, 142], prostate [143, 144], bladder [145, 146], cervical [147, 148], gastric [56, 149], and skin [150, 151] cancer.”
BackgroundDrug screening on digital microfluidics for cancer precision medicine
Zhai, J., Liu, Y., Ji, W., Huang, X., Wang, P., Li, Y., Li, H., Wong, A. H., Zhou, X., Chen, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48616-3 · Cited by 133
“Another approach to observe the primary tumor cell responses to drug involved the use of a thin slice of tumor which already has the same microenvironment as an in-vivo tumor 59,67 .”
Breakthroughs and Applications of Organ-on-a-Chip Technology
Koyilot, M. C., Natarajan, P., Hunt, C. R., Sivarajkumar, S., Roy, R., Joglekar, S. S., Pandita, S., Tong, C. W.-C., Marakkar, S., Subramanian, L., et al. (2022) · Cells · doi:10.3390/cells11111828 · Cited by 117
Creating a kidney organoid-vasculature interaction model using a novel organ-on-chip system
Menéndez, A. B.-C., Du, Z., van den Bosch, T. P. P., Othman, A., Gaio, N., Silvestri, C., Quirós-Solano, W. F., Lin, H., Korevaar, S. S., Merino, A. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24945-5 · Cited by 81
Self-citation
Metadata
- Authors
- Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., Odijk, H., van de Ven, M., de Ridder, C. M. A., van Weerden, W. M., Jonkers, J., Dekker, R., Taneja, N., Kanaar, R., & van Gent, D. C.
- Affiliations
- Manipal Academy of Higher Education (IN)
- 3Department of Microelectronics, Electronic Components, Technology and Materials, Delft University of Technology, Delft, the Netherlands.
- Erasmus MC (NL)
- 4BIOND Solutions B.V., Delft, the Netherlands.
- 7Philips Research, Eindhoven, the Netherlands.
- 8Preclinical Intervention Unit, Mouse Clinic for Cancer and Ageing, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- 9Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
- The Netherlands Cancer Institute (NL)
- Delft University of Technology (NL)
- 1Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
- ORCID
- Venue
- Cancer Research
- Published
- 2021-12-06
- Volume
- 82
- Issue
- 3
- Pages
- 510-520
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC9397621
- OpenAlex
- W4200376156
- Cited by
- 61
- References
- 52
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 12 · 2023: 13 · 2022: 7
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc-nd)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Research Repository (Delft University of Technology) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- KWF Kankerbestrijding (KWF11011)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (737.016.011)
- Electronic Components and Systems for European Leadership (H2020-ECSEL-2019-IA-876190)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug response prediction, microfluidic platform, breast cancer, prostate cancer, cisplatin, apalutamide, chemosensitivity, xenograft models, personalized treatment, silicon microfluidics, primary tumor tissue
- MeSH terms
- Humans, Organ Culture Techniques, Gene Expression, Microfluidics, Biomarkers, Pharmacological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. https://app.cochat.ai/papers/10.1158/0008-5472.can-21-0799
- The paper
- Chakrabarty, S., Quiros-Solano, W. F., Kuijten, M. M. P., Haspels, B., Mallya, S., Lo, C. S. Y., Othman, A., Silvestri, C., van de Stolpe, A., Gaio, N., Odijk, H., van de Ven, M., de Ridder, C. M. A., van Weerden, W. M., Jonkers, J., Dekker, R., Taneja, N., Kanaar, R., & van Gent, D. C. (2022). A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture. Cancer Research. https://doi.org/10.1158/0008-5472.can-21-0799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.